Arrhythmogenic Right Ventricular Cardiomyopathy

Arrhythmogenic right ventricular cardiomyopathy (ARVC) encompasses a group of conditions characterized by right ventricular fibrofatty infiltration, with a predominant arrhythmic presentation. First described in the late 1970s and early 1980s, it is now frequently recognized to have biventricular in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Clinical electrophysiology Jg. 8; H. 4; S. 533
Hauptverfasser: Krahn, Andrew D, Wilde, Arthur A M, Calkins, Hugh, La Gerche, Andre, Cadrin-Tourigny, Julia, Roberts, Jason D, Han, Hui-Chen
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.04.2022
Schlagworte:
Arrhythmogenic Right Ventricular Dysplasia - diagnosis
Arrhythmogenic Right Ventricular Dysplasia - genetics
Arrhythmogenic Right Ventricular Dysplasia - therapy
Catheter Ablation - adverse effects
Death, Sudden, Cardiac - etiology
Death, Sudden, Cardiac - prevention & control
Defibrillators, Implantable - adverse effects
Female
Humans
Male
Tachycardia, Ventricular - surgery
ventricular arrhythmia
sudden death
cardiomyopathy
inherited
ISSN:2405-5018, 2405-5018
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Arrhythmogenic right ventricular cardiomyopathy (ARVC) encompasses a group of conditions characterized by right ventricular fibrofatty infiltration, with a predominant arrhythmic presentation. First described in the late 1970s and early 1980s, it is now frequently recognized to have biventricular involvement. The prevalence is ∼1:2,000 to 1:5,000, depending on geographic location, and it has a slight male predominance. The diagnosis of ARVC is determined on the basis of fulfillment of task force criteria incorporating electrophysiological parameters, cardiac imaging findings, genetic factors, and histopathologic features. Risk stratification of patients with ARVC aims to identify those who are at increased risk of sudden cardiac death or sustained ventricular tachycardia. Factors including age, sex, electrophysiological features, and cardiac imaging investigations all contribute to risk stratification. The current management of ARVC includes exercise restriction, β-blocker therapy, consideration for implantable cardioverter-defibrillator insertion, and catheter ablation. This review summarizes our current understanding of ARVC and provides clinicians with a practical approach to diagnosis and management.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2405-5018
2405-5018
DOI:10.1016/j.jacep.2021.12.002